PROTAC ER Degrader-3

Catalog No. A18519

PROTAC ER Degrader-3 is an intermediate for synthesis of PAC. PAC, consists the ADCs linker and PROTACs, conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2. PAC conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab).
Catalog Num A18519
M. Wt 1220.41
Formula C71H77N7O12
Purity >98%
Storage at -20 °C 3 years (powder form); at -20 °C 6 months (Solution base)
CAS No. 2158322-29-1
Synonyms
SMILES OC1=CC=C(/C(C2=CC=C(OCCN(C)C(COCCOCCNC(C3=CC=C(C(N4[[email protected]@H](C)[[email protected]](NC([[email protected]](C)N(C(OC(C)(C)C)=O)C)=O)C(N(CC5=C(OC)C=CC6=C5C=CC=C6)C7=C4C=C(C#N)C=C7)=O)=O)C=C3)=O)=O)C=C2)=C(CC)/C8=CC=CC=C8)C=C1
PROTAC ER Degrader-3 is an intermediate for synthesis of PAC. PAC, consists the ADCs linker and PROTACs, conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2. PAC conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab).
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 8.19 mL 40.97 mL 81.94 mL
0.5 mM 1.64 mL 8.19 mL 16.39 mL
1 mM 0.82 mL 4.1 mL 8.19 mL
5 mM 0.16 mL 0.82 mL 1.64 mL

*The above data is based on the productmolecular weight 1220.41. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.